Innovent’s Adalimumab And Bevacizumab Get New Indications In China
New Indications Include Treatment of Psoriasis, Uveitis And Glioblastoma
• By Akriti Seth
Innovent receives NMPA approval for new indications for its adalimumab and bevacizumab biosimilars • Source: Shutterstock 
